A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
CRA adds Kevin Williams, Yale School of Management Professor, as academic affiliate to Antitrust Practice
“I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in...